Jonaki Bose has been a federal statistician for 27 years. She’s worked in the Education, Transportation, and Health and Human Services departments. Now, as a senior adviser, she works on interesting production challenges, mentors, and performs methodological work with like-minded colleagues interested in furthering the production and use of health statistics.
Tamara G. Kolda’s career began at the dawn of the internet, in the pre-Google era. Since then, she has worked at the intersection of mathematics, computing, and data. She was awarded the Alston S. Householder Postdoctoral Fellow in Scientific Computing at Oak Ridge National Labs in Tennessee after completing her doctorate and worked for two decades at Sandia National Labs in California. She has benefitted from the advice and guidance of many statisticians along the way and finds the community to be highly collegial. She helped launch and serves as founding editor-in-chief of the SIAM Journal on Mathematics of Data Science, an academic journal focused on the mathematical and statistical foundations of data science methods.
Significance magazine publishes stories about statistics and data science written by experts for everyone. Currently needed is an ASA member who is an expert statistician or data scientist to join the magazine’s editorial board.
Ni Zhao’s career as a biostatistician followed a convoluted path. When she was a kid, her parents dreamed she would become a medical doctor. She partly had the same wish—she wanted to work toward improving human health and well-being. Yet, she was also fascinated by the beauty of mathematics and didn’t think there was a way to combine math and medicine until she discovered biostatistics. Now, as an assistant professor of biostatistics at The Johns Hopkins University, she collaborates with top-notch researchers and participates in frontline research.
During the ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop this past September, Godwin Yung and Dooti Roy held a roundtable discussion on increasing Justice, Equity, Diversity, and Inclusion (JEDI) in clinical trials. Here, they share three takeaways from the conversation.
